Drug Trial Radar · NCT07038824
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 30, 2025
Primary completion
Mar 1, 2029
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Entrada Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-45 is, learn about any side effects, and look at the potential positive effects of ENTR-601-45, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-45 and placebo are both called study treatments. The study has 2 parts: Part A: to evaluate if ENTR-601-45 is safe and to determine the best dose of ENTR-601-45 for Part B. Part B: to further evaluate the effect and safety of ENTR-601-45 at the dose determined in Part A. Participants will be able to roll into an open-label treatment period during which the safety and efficacy of extended dosing will be evaluated. Participants will: * Receive study treatment in the form of multiple intravenous (IV) infusions (slow injection) into a vein over the course of several weeks in Part A and in Part B * Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, muscle biopsies and exercise tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a result of the study drug. Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.
Conditions
- Duchenne Muscular Dystrophy (DMD)
Interventions
ENTR-601-45Drug
intravenous infusion
ENTR-601-45 - matching placeboDrug
intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period).Time frame: From baseline through End of Study (up to 62 weeks).
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
University Hospital Gent
Ghent, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Centre Hospitalier Régional de la Citadelle
Liège, Belgium · Recruiting
IRCCS Ospedale San Raffaele
Milan, Italy · Recruiting
Ospedale Pediatrico Bambino Gesu
Rome, Italy · Recruiting
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Italy · Recruiting
Leids Universitair Medisch Centrum
Leiden, Netherlands · Recruiting
Stichting Radboud Universitair Medisch Centrum
Nijmegen, Netherlands · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Sant Joan de Deu
Barcelona, Spain · Recruiting
Leeds General Infirmary
Leeds, United Kingdom · Recruiting
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom · Recruiting
Great Ormond Street Hospital for Children
London, United Kingdom · Recruiting
Royal Manchester Children's Hospital
Manchester, United Kingdom · Not yet recruiting
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.